Andrew D. Reddick
President & Chief Executive Officer
Acura Pharmaceuticals, Inc.
www.acurapharm.com

Andy Reddick has been director of Acura since August 2004 and President and Chief Executive Officer since August, 2003.  From April 2000 to September, 2002 Mr. Reddick was Chief Operating Officer and Sr. Vice President of Commercial Operations for Adolor Corporation.  Adolor is a specialty pharmaceutical company focused on opioid receptor technology and related product development and commercialization.  From June, 1999 to March, 2000 Mr. Reddick was President of Faulding Laboratories, Inc., a specialty pharmaceutical division focused on commercializing branded opioid analgesics and related products.  From August, 1996 to June, 1999, he was Executive Vice President Marketing, Sales and Business Development with Purepac Pharmaceuticals, a major developer, manufacturer and distributor of generic pharmaceuticals, including a broad range of controlled substances.  In addition, Mr. Reddick served for more than 20 years on the management team and in senior level roles at Burroughs Wellcome Co., an international pharmaceutical company based in the United Kingdom.

Mr. Reddick holds a Bachelor of Arts degree in Biology from the University of California and a Master of Business Administration from Duke University.

Mr. Reddick serves on Acura's compensation committee.